Prognostic value of REG3α concentrations at onset of GVHD. (A) Patients were classified by response to GVHD therapy after 4 weeks (N = 160). (B-D) Patients were classified by REG3α concentration: low (≤ 151 ng/mL, n = 81; thin line) and high (> 151 ng/mL, n = 81; thick line). (B) NRM (34% vs 59%, P < .001) (C) Relapse mortality (17% vs 14%, P = .59). (D) One-year survival (48% vs 27%, P = .001). All P values are adjusted for donor source, HLA match, conditioning intensity, recipient age, and baseline disease severity according to the Center for International Blood and Marrow Transplant Research (CIBMTR) guidelines. (E) One-year NRM for patients classified by number of risk factors at GVHD onset, using clinical stage (high risk = stage 2-4) and histologic grade (high risk = grade 4); 0 (purple, NRM = 26%); 1 (red, NRM = 60%); 2 (blue, NRM = 71%); 0 vs 1, P < .001; 1 vs 2, P = .006. (F) One-year NRM for patients classified by number of risk factors at the time of GVHD diagnosis as in panel E and including REG3α concentration (high risk > 151 ng/mL); 0 (purple, NRM = 25%); 1 (red, NRM = 34%); 2 (purple, NRM = 66%); 3 (brown, NRM = 86%); 0 vs 1, P = .2; 1 vs 2, P < .001; 2 vs 3, P < .001.